🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07473349
Starting soon Not applicable

Diagnostic Accuracy of Clinical Tests and Diagnostic Criteria for Piriformis Syndrome

NCT07473349 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-03-15
Last updated
2026-03-17

Condition(s) studied

Piriformis SyndromeGluteal Pain

Investigational drug(s) / intervention(s)

Ultrasound-Guided Piriformis Injection

Ultrasound-Guided Piriformis Injection: Ultrasound-guided injection of 5 mL of 2% lidocaine into the piriformis muscle for diagnostic confirmation. A patient-reported pain reduction of 50% or more at 1 hour after injection will be considered confirmation of piriformis syndrome.

Study summary

Piriformis syndrome is a clinical condition characterized by buttock pain and/or sciatic-like symptoms, and its diagnosis remains challenging because there is no universally accepted diagnostic standard. This study aims to evaluate the diagnostic accuracy of commonly used diagnostic criteria and clinical tests for piriformis syndrome. Participants with suspected piriformis syndrome will undergo standardized physical examination and assessment of predefined diagnostic criteria. Ultrasound-guided injection of 5 mL of 2% lidocaine into the piriformis muscle will be used as the reference diagnostic procedure. A reduction of 50% or more in pain after injection will be considered confirmation of piriformis syndrome. The diagnostic performance of clinical tests and diagnostic criteria will be analyzed accordingly.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 to 75 years * Presentation with gluteal pain * Pain on palpation in the piriformis region Exclusion Criteria: * History of injection to the lumbar, hip, or gluteal region within the last 3 months,including steroid, hyaluronic acid, or similar injections * History of hip surgery * Presence of active inflammatory rheumatic disease, including rheumatoid arthritis, ankylosing spondylitis, polymyalgia rheumatica, vasculitis, or similar conditions * Active skin or subcutaneous soft tissue infection in the gluteal region * Use of anticoagulant therapy that may contraindicate injection * Presence of a bleeding disorder * Uncontrolled diabetes mellitus and/or hypertension * History of neurological disease * Pregnancy or lactation * Presence of a psychiatric disorder * Known allergy to the injection agents * History of malignancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Istanbul Turkey (Türkiye)

More Istanbul University - Cerrahpasa trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07473349 on ClinicalTrials.gov ↗ ← All trials in Turkey